Curetis AG, the molecular diagnostics company from the Stuttgart area (Germany), has now announced its launch of an initial public offering (IPO). Previously, this biotech has raised €63.5M to develop its Unyvero Platform for testing infectious disease, including Pneumonia and biomarkers in antibiotic resistance. This new IPO aims to further commercialize this system and expand the global reach of Curetis.
Hospital acquired infections (HAI) result in deaths of up to 99,000 patients per year in the US alone. Therefore, the quest for early detection of such infectious diseases is subject to a refined area of biotech R&D. The Unyvero platform from Curetis uses disposable cartridges to detect Pneumonia (and up to 61 other micro-organisms which cause disease) as well as pick-up biomarkers seen in HAIs.